Stockreport

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]

Rapport Therapeutics, Inc.  (RAPP) 
PDF The change represents 0.31% of Cormorant's reportable 13F assets under management. The post-trade stake totaled 3,192,521 shares worth $94.82 million. Rapport Thera [Read more]